chevron_leftBack
As of 24 April 2025, NetraMark Holdings Inc. has a market cap of $88.77M USD, ranking #21349 globally and #581 in Canada. It ranks #2131 in the Healthcare sector, and #96 in the Health Information Services industry.
Key Stats
Market Cap
$88.77MUSD
122.94M CAD
Enterprise Value
$87.83MUSD
121.64M CAD
Revenue (TTM)
$607.93KUSD
841.91K CAD
Net Income (TTM)
-$2.32MUSD
-3.21M CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Health Information Services
CEO
George Achilleos
open_in_new
Founded
2016
Website
netramark.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -11% | 2.8% | 64% | 402% | 377% |
Upcoming Earnings
Earnings Date
Tue, May 13
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AIAI
NetraMark Holdings Inc Ordinary Shares
ISIN: CA64119M1059
Shares Out.:
Shares Outstanding:
75.492M1
Shares Float:
58.073M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.51 CAD | |
|
AIAI
NetraMark Holdings Inc Ordinary Shares
ISIN: CA64119M1059
|
1.48 CAD | |
|
AINMF
NetraMark Holdings Inc Ordinary Shares
ISIN: CA64119M1059
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.12 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NetraMark Holdings Inc.
NetraMark Holdings Inc. develops artificial intelligence and machine learning solutions for the pharmaceutical industry in Canada. The company’s product suite comprises Netra Shatter; Netra Health Atlas; and NetraAi that is designed to help interact and explore with different perspective of the data for clinical trials. It provides NetraPlacebo module that analyzes past trial data to determine what drives placebo responses to guide inclusion/exclusion criteria; and Netra GPT module that offers insights from past clinical trials about the patient’s population by utilizing established medical literature. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. The company was founded in 2016 and is headquartered in Toronto, Canada.
